- $196.59m
- $70.49m
- $2.27m
Annual balance sheet for Korro Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 119 | 55.2 | 166 | 126 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | — | — | — | 1.7 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 120 | 57.1 | 173 | 132 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 6.45 | 11.9 | 42.8 | 51.5 |
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 128 | 73.7 | 222 | 226 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 4.95 | 8.7 | 19.5 | 15 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 5.92 | 8.91 | 51.8 | 65.8 |
| Redeemable Preferred Stock | ||||
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 122 | 64.8 | 170 | 160 |
| Total Liabilities & Shareholders' Equity | 128 | 73.7 | 222 | 226 |
| Total Common Shares Outstanding |